Cocrystal Pharma (NASDAQ:COCP) Posts Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Posted by Casey Walker on Aug 13th, 2026

Cocrystal Pharma (NASDAQ:COCP – Get Free Report) posted its earnings results on Thursday. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.06), FiscalAI reports.

Cocrystal Pharma Stock Down 1.8%

COCP stock traded down $0.02 during trading on Thursday, hitting $1.10. The company had a trading volume of 35,956 shares, compared to its average volume of 1,029,859. The firm has a 50-day moving average price of $0.99 and a 200-day moving average price of $1.10. Cocrystal Pharma has a 12 month low of $0.76 and a 12 month high of $2.67. The stock has a market cap of $15.17 million, a price-to-earnings ratio of -1.51 and a beta of 1.43.

Hedge Funds Weigh In On Cocrystal Pharma

An institutional investor recently bought a new position in Cocrystal Pharma stock. DRW Securities LLC acquired a new position in Cocrystal Pharma, Inc. (NASDAQ:COCP – Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned 0.24% of Cocrystal Pharma as of its most recent SEC filing. Institutional investors own 6.72% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded Cocrystal Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

Read Our Latest Research Report on COCP

Cocrystal Pharma Company Profile

(Get Free Report)

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.